Neuraxis, INC

Listed Company

NRXSCIK 0001933567NYSENon-AcceleratedSmaller ReportingEmerging GrowthElectromedical & Electrotherapeutic ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$3.57M

Net Income

$-7.80M

Total Assets

$6.40M

Equity

$3.40M

Shares Out

11.19M

Op. Cash Flow

$-6.43M

Business

Neuraxis, INC is a medical technology company developing neuromodulation therapies using its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) platform to address chronic and debilitating conditions in children and adults. It offers FDA-cleared devices and point-of-care diagnostic tools, primarily the IB‑Stim PENFS system for pediatric functional abdominal pain associated with IBS, and the Rectal Expulsion Device (RED), along with licensed products and research-stage indications. Its business comprises commercial device sales, diagnostic products, licensing arrangements and ongoing clinical development programs. Neuraxis markets primarily to U.S. children’s hospitals and pediatric clinics through a direct sales force, digital channels, academic society engagement and point-of-care distribution.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Net sales	4	3	2	3
Cost of goods sold	562,916	362,002	303,345	297,060
Gross profit	3	2	2	2
Selling expenses	2	1	323,569	410,883
Research and development	493,611	433,614	169,315	225,610
General and administrative	8	8	8	5
Operating loss	−8	−7	−7	−3
Financing charges	−30,240	−230,824	−2,772	−2
Interest expense	−73,969	−174,328	−476,416	−318,666
Change in fair value of warrant liability	−7,634	−941	844,854	606,049
Amortization of debt discount and issuance cost	—	−126,387	−5	−98,935
Extinguishment of debt liabilities	—	—	−4	—
Other income	141,196	33,620	15,133	11,956
Other expense	—	−585,824	−10,355	—
Total other income (expense), net	29,353	−1	−8	−1
Net loss	−8	−8	−15	−5
Preferred stock dividends	−814,597	−211,268	—	—
Net loss available to common stockholders	−9	−8	−15	—
Basic loss per share	−0.95	−1.22	−4.5	−2.77
Diluted loss per share	−0.95	−1.22	−4.5	−2.77
Basic	9	7	3	2
Diluted	9	7	3	2

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2022 2022-12-31
Cash and cash equivalents	5	4	78,560	761,249	253,699
Accounts receivable, net of credit losses of $7,326 and $5,000 as of December 31, 2025 and 2024, respectively	195,703	244,618	73,167	132,382	174,399
Inventories, net of reserves of $34,524 and $4,454 as of December 31, 2025 and 2024, respectively	257,132	44,328	21,220	34,530	48,133
Prepaids and other current assets	315,283	280,367	69,663	38,693	726
Total current assets	6	4	242,610	966,854	476,957
Property and Equipment, at Cost:	382,465	464,402	436,626	420,586	405,845
Less - accumulated depreciation	−306,901	−374,420	−348,074	−340,260	−317,834
Property and equipment, net	75,564	89,982	88,552	80,326	88,011
Operating lease right of use asset, net	261,565	284,656	70,263	78,043	101,382
Intangible assets, net	274,778	96,588	108,073	110,695	77,558
Other non-current assets	58,939	20,163	—	—	—
Total Assets	6	5	509,498	1	1
Accounts payable	139,365	596,946	1	566,649	2
Accrued expenses	2	2	401,088	280,063	834,062
Notes payable	148,293	154,152	—	—	—
Current portion of operating lease payable	65,752	62,754	49,127	45,194	33,395
Customer deposits	28,660	32,527	74,947	68,972	59,174
Warrant liabilities	16,800	9,166	8,225	168,269	2
Total current liabilities	3	2	2	2	7
Operating lease payable, net of current portion	202,566	256,499	27,071	39,353	76,199
Other non-current liabilities	9,999	—	—	—	—
Total non-current liabilities	212,565	256,499	27,071	—	76,199
Total liabilities	3	3	2	2	7
Commitments and contingencies (see note 17)	—	—	—	—	—
Convertible Series B Preferred stock, $0.001 par value; 5,000,000 shares authorized; 3,796,907 and 4,280,939 shares issued and outstanding as of December 31, 2025 and 2024, respectively	3,797	4,281	—	—	—
Common stock, $0.001 par value; 100,000,000 shares authorized; 10,652,812 and 6,990,227 issued and outstanding as of December 31, 2025 and 2024, respectively	10,653	6,990	6,509	5,149	1,963
Additional paid in capital	68	59	47	46	28
Accumulated deficit	−65	−57	−49	−47	−34
Total stockholders equity	3	2	−1	−1	−6
Total Liabilities and Stockholders Equity	6	5	509,498	1	1

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Depreciation and amortization	59,501	37,831	—	—
Provisions for losses on accounts receivable	2,326	7,395	25,281	19,505
Provision for losses on inventory	30,070	4,454	—	—
Loss on disposal of property and equipment	7,878	—	—	—
Non-cash lease expense	23,092	32,075	31,119	26,593
Stock based compensation	596,852	227,000	—	27,319
Issuance of common stock for non-cash consideration	—	1	750,000	—
Fair value of warrants issued for non-cash consideration	—	157,745	—	—
Accounts receivable	46,589	−178,845	75,951	−78,603
Inventory	−242,874	−32,500	26,913	−8,953
Prepaids and other current assets	240,975	56,157	−68,937	14,944
Accounts payable	−457,583	−607,273	−387,897	1
Accrued expenses	1	949,693	−294,154	272,425
Customer deposits	−3,867	−42,420	15,773	−10,163
Operating lease liability	−50,935	−3,414	−33,396	−27,582
Other non-current liabilities	−4,913	—	—	—
Net cash used by operating activities	−6	−6	−7	−2
Additions to property and equipment	−31,150	−27,776	−30,781	−1,390
Additions to intangible assets	−100,000	—	−41,000	−59,815
Net cash used by investing activities	−131,150	−27,776	−71,781	−61,205
Proceeds from issuance of common stock, net of issuance costs	8	—	5	—
Proceeds from issuance of Series B preferred stock	—	5	—	—
Deferred offering costs paid	−712,669	—	—	−736,736
Proceeds from exercised warrants	1	26,180	—	—
Principal payments on notes payable	−281,751	−275,994	−4	−163,214
Proceeds from convertible notes	—	5	5	3
Financing fees paid	—	−194,502	−552,000	−130,000
Net cash provided by financing activities	8	10	7	2
Net Increase in Cash and Cash Equivalents	1	4	−175,139	−67,159
Cash paid for interest	11,854	33,830	214,562	202,781
Cash paid for federal income taxes	—	—	—	—
Cash refunded for state income taxes	13,140	10,164	—	—
Recognition of right of use asset	37,970	284,339	—	—
Derecognition of right of use asset	29,014	—	—	—
Conversion of convertible promissory notes to Series B preferred stock	—	5	—	—
Fair value of warrants from debt discount in convertible notes classified as additional paid in capital	—	97,465	—	—
Write-off of debt discount on convertible notes classified as additional paid in capital	—	165,577	—	—
Issuance of note payable to financing company for insurance premiums and software subscription	292,253	282,086	—	—
Common stock issued upon cashless exercise of warrants	186	—	—	—
Common stock issued upon cashless conversion of Series B Preferred Stock	484	—	—	—
Common stock issued for services accrued as of December 31, 2024	112,493	—	—	—
Common stock issued upon settlement of certain claims	3,673	—	—	—
Intangible asset purchase	100,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro